These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 25394654)

  • 1. Contingencies of the will: Uses of harm reduction and the disease model of addiction among health care practitioners.
    Szott K
    Health (London); 2015 Sep; 19(5):507-22. PubMed ID: 25394654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Training the next generation of providers in addiction medicine.
    Rasyidi E; Wilkins JN; Danovitch I
    Psychiatr Clin North Am; 2012 Jun; 35(2):461-80. PubMed ID: 22640766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beyond human rights and public health: citizenship issues in harm reduction.
    Chen JS
    Int J Drug Policy; 2011 May; 22(3):184-8. PubMed ID: 21242083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient perspectives on a harm reduction-oriented addiction medicine consultation team implemented in a large acute care hospital.
    Hyshka E; Morris H; Anderson-Baron J; Nixon L; Dong K; Salvalaggio G
    Drug Alcohol Depend; 2019 Nov; 204():107523. PubMed ID: 31541875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Examining the ethical boundaries of harm reduction: from addictions to general psychiatry.
    Lev-Ran S; Nitzan U; Fennig S
    Isr J Psychiatry Relat Sci; 2014; 51(3):175-80. PubMed ID: 25618280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integrating multiple programme and policy approaches to hepatitis C prevention and care for injection drug users: a comprehensive approach.
    Birkhead GS; Klein SJ; Candelas AR; O'Connell DA; Rothman JR; Feldman IS; Tsui DS; Cotroneo RA; Flanigan CA
    Int J Drug Policy; 2007 Oct; 18(5):417-25. PubMed ID: 17854731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The place of volition in addiction: differing approaches and their implications for policy and service provision.
    Karasaki M; Fraser S; Moore D; Dietze P
    Drug Alcohol Rev; 2013 Mar; 32(2):195-204. PubMed ID: 22963577
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Addiction, agency, and the politics of self-control: doing harm reduction in a heroin users' group.
    Gowan T; Whetstone S; Andic T
    Soc Sci Med; 2012 Apr; 74(8):1251-60. PubMed ID: 22385814
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integration of a community-based harm reduction program into a safety net hospital: a qualitative study.
    Khan GK; Harvey L; Johnson S; Long P; Kimmel S; Pierre C; Drainoni ML
    Harm Reduct J; 2022 Apr; 19(1):35. PubMed ID: 35414072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk environments and drug harms: a social science for harm reduction approach.
    Rhodes T
    Int J Drug Policy; 2009 May; 20(3):193-201. PubMed ID: 19147339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Living with addiction: the perspectives of drug using and non-using individuals about sharing space in a hospital setting.
    Strike C; Guta A; de Prinse K; Switzer S; Chan Carusone S
    Int J Drug Policy; 2014 May; 25(3):640-9. PubMed ID: 24679487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The making of the chronic addict.
    Järvinen M; Andersen D
    Subst Use Misuse; 2009; 44(6):865-85. PubMed ID: 19444727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. On Addiction, Complexity, and Freedom: Toward a Liberation-Focused Addiction Treatment.
    Kellogg S
    J Psychoactive Drugs; 2019; 51(1):85-92. PubMed ID: 30653394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contested space in the pharmacy: public attitudes to pharmacy harm reduction services in the West of Scotland.
    Gidman W; Coomber R
    Res Social Adm Pharm; 2014; 10(3):576-87. PubMed ID: 24021859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Challenges and opportunities to integrating family members of injection drug users into harm reduction efforts within the Atlantic Canadian context.
    Jackson LA; Dykeman M; Gahagan J; Karabanow J; Parker J
    Int J Drug Policy; 2011 Sep; 22(5):385-92. PubMed ID: 21742479
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New systems of care for substance use disorders: treatment, finance, and technology under health care reform.
    Pating DR; Miller MM; Goplerud E; Martin J; Ziedonis DM
    Psychiatr Clin North Am; 2012 Jun; 35(2):327-56. PubMed ID: 22640759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suboxone misuse along the opiate maintenance treatment pathway.
    Furst RT
    J Addict Dis; 2013; 32(1):53-67. PubMed ID: 23480248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advocacy for harm reduction in China: a new era dawns.
    Reid G; Aitken C
    Int J Drug Policy; 2009 Jul; 20(4):365-70. PubMed ID: 19097773
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A qualitative analysis of transitions to heroin injection in Kenya: implications for HIV prevention and harm reduction.
    Guise A; Dimova M; Ndimbii J; Clark P; Rhodes T
    Harm Reduct J; 2015 Sep; 12():27. PubMed ID: 26337729
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Harm reduction theory: users' culture, micro-social indigenous harm reduction, and the self-organization and outside-organizing of users' groups.
    Friedman SR; de Jong W; Rossi D; Touzé G; Rockwell R; Des Jarlais DC; Elovich R
    Int J Drug Policy; 2007 Mar; 18(2):107-17. PubMed ID: 17689353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.